Oxford Biomedica signed an 18-month supply agreement in September 2020 with AstraZeneca for the large-scale commercial manufacture of the adenovirus vector-based Covid-19 vaccine, AZD1222.
AstraZeneca has now requested that Oxford Biomedica increase the number of batches it is manufacturing in the second half of 2021. Oxford Biomedica is raising revenue guidance for expected cumulative revenues from AstraZeneca by the end of 2021 from in excess of £50 million to in excess of £100 million.
